1-4 of 4
Lawrence Mayer
Close
Sort by
Journal Articles

Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation

David K. Edwards, V, BA, BS, Nathalie Javidi-Sharifi, Angela Rofelty, Claire Rosenfeld, Riley Roth-Carter, Paul Tardi, PhD, Lawrence Mayer, PhD, Jeffrey W. Tyner
Journal: Blood
Blood (2016) 128 (22): 5124.
https://doi.org/10.1182/blood.V128.22.5124.5124
Published: 2016
Journal Articles

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD, Marc M Loriaux, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2886.
https://doi.org/10.1182/blood.V116.21.2886.2886
Published: 2010
Journal Articles

Synergistic Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts Is Associated with Liposome-Mediated Bone Marrow Drug Accumulation, Intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy.

Lawrence Mayer, PhD, Wahseng Lim, PhD, Nancy Dos Santos, PhD, Sherwin Xie, PhD, Andrea Hopkins, Ruby Huang, Lindsey Wilkins, Sarah Kelly, David Bermudes, PhD, Troy Harasym, PhD, Paul Tardi, PhD
Journal: Blood
Blood (2008) 112 (11): 942.
https://doi.org/10.1182/blood.V112.11.942.942
Published: 2008
Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ekatherine Asatiani, Tania J. Curcio, Michelle K. Burton, Marjorie Fricano, Amanda R. Begley, Christine Swenson, Lawrence Mayer, Andrew S. Janoff, Arthur C. Louie
Journal: Blood
Blood (2007) 110 (11): 900.
https://doi.org/10.1182/blood.V110.11.900.900
Published: 2007